Jens K.
- Country
- Germany
- Department
- Schwerpunkt Pneumologie u. Beatmungsmedizin
Research Overview
- Phase 3 Multicenter Trial Comparing Repotrectinib and Crizotinib in TKI-naïve ROS1-positive Advanced Non-Small Cell Lung Cancer
- Phase 3 Randomized Study of Pembrolizumab and Sacituzumab Govitecan Combination Versus Pembrolizumab Monotherapy in PD-L1 TPS ≥50% Metastatic NSCLC
- Efficacy of Durvalumab and Tremelimumab as Consolidation Therapy in Limited Stage Small-Cell Lung Cancer Post-Concurrent Chemoradiation Therapy
Data & Insights
Has run more than one trial at 184 of 345 partner sites.
Specializations
Early Stage Lung Cancer
The investigator specializes in treating early-stage non-small cell lung cancer, with particular focus on post-surgical therapeutic approaches and neoadjuvant treatments. Their research encompasses both stage I adenocarcinoma and resectable stage II-IIIB NSCLC.
- Adjuvant therapy optimization
- Surgical outcome improvement
- Early-stage disease management
Advanced Lung Cancer
The investigator focuses on treating metastatic non-small cell lung cancer, including both squamous and non-squamous subtypes. Their expertise extends to cases with specific molecular characteristics like EGFR mutations, KRAS G12C mutations, and PD-L1 expression.
- Targeted therapy development
- Immunotherapy applications
- Biomarker-driven treatments
Novel Therapeutic Approaches
The investigator explores innovative treatment combinations including immunotherapy-chemotherapy combinations and targeted molecular therapies. Their work includes evaluation of novel agents for small-cell lung cancer and various stages of non-small cell lung cancer.
- Combination therapy strategies
- Treatment resistance management
- Therapeutic sequencing
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.